Cervical Cancer in Women with Normal Papanicolaou Tests: A Korean Nationwide Cohort Study
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study aimed to evaluate the risk of cervical cancer diagnosed within 1 year after the last of multiple consecutive normal Papanicolau (Pap) tests.Materials and Methods The database of the National Health Insurance Service was used. We obtained Pap test data for 11,052,116 women aged 30-79 between 2007-2012. The cumulative incidence rates and 5-year overall survival rates of cervical cancer diagnosed within 1 year after the last normal Pap test were compared between women with one (N1), two (N2), and three consecutive normal Pap tests (N3). Women who did not receive a Pap test during the study period were assigned in the N0 group.Results The 1-year cumulative incidence rates of cervical cancer were 58.9, 24.6, 20.3, and 14.2 per 105 in the N0, N1, N2, and N3 groups, respectively. Compared to the N1 group, the risk of cervical cancer diagnosed within 1 year of the last normal Pap test decreased by 17% (relative risk [RR], 0.825; 95% confidence interval [CI], 0.716 to 0.951) in the N2 group and 42% (RR, 0.578; 95% CI, 0.480 to 0.695) in the N3 group. However, the 5-year survival rate in women diagnosed with cervical cancer within 1 year of the last normal Pap test in the N3 group was not higher than that of the N1 group (79.6% vs. 81.3%, p=0.706).Conclusion As normal Pap tests are consecutively repeated, cervical cancer risk significantly decreases. However, previous consecutive normal Pap tests are not associated with improving survival outcomes in women shortly diagnosed with cervical cancer after the last normal Pap test.
Abstract
Purpose This study aimed to evaluate the risk of cervical cancer diagnosed within 1 year after the last of multiple consecutive normal Papanicolau (Pap) tests.Materials and Methods The database of the National Health Insurance Service was used. We obtained Pap test data for 11,052,116 women aged 30-79 between 2007-2012. The cumulative incidence rates and 5-year overall survival rates of cervical cancer diagnosed within 1 year after the last normal Pap test were compared between women with one (N1), two (N2), and three consecutive normal Pap tests (N3). Women who did not receive a Pap test during the study period were assigned in the N0 group.Results The 1-year cumulative incidence rates of cervical cancer were 58.9, 24.6, 20.3, and 14.2 per 105 in the N0, N1, N2, and N3 groups, respectively. Compared to the N1 group, the risk of cervical cancer diagnosed within 1 year of the last normal Pap test decreased by 17% (relative risk [RR], 0.825; 95% confidence interval [CI], 0.716 to 0.951) in the N2 group and 42% (RR, 0.578; 95% CI, 0.480 to 0.695) in the N3 group. However, the 5-year survival rate in women diagnosed with cervical cancer within 1 year of the last normal Pap test in the N3 group was not higher than that of the N1 group (79.6% vs. 81.3%, p=0.706).Conclusion As normal Pap tests are consecutively repeated, cervical cancer risk significantly decreases. However, previous consecutive normal Pap tests are not associated with improving survival outcomes in women shortly diagnosed with cervical cancer after the last normal Pap test.
참고문헌 (29)
- Bray F, "Global cancer statistics 2018 : GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries", CA Cancer J Clin, 68, pp.394~424 (2018)
- Arbyn M, "Trends of cervical cancer mortality in the member states of the European Union", Eur J Cancer, 45, pp.2640~2648 (2009)
- Wingo PA, "Long-term trends in cancer mortality in the United States, 1930-1998", Cancer, 97, pp.3133~3275 (2003)
- 임명철, "Incidence of cervical, endometrial, and ovarian cancer in Korea during 1999–2015", Journal of Gynecologic Oncology, 30(1), pp.1~8 (2019), 대한부인종양학회[DOI]
- Papanicolaou GN, "The diagnostic value of vaginal smears in carcinoma of the uterus. 1941", Arch Pathol Lab Med, 121, pp.211~224 (1997)
- 공태욱, "High-risk human papillomavirus testing as a primary screening for cervical cancer: position statement by the Korean Society of Obstetrics and Gynecology and the Korean Society of Gynecologic Oncology", Journal of Gynecologic Oncology, 31(1), pp.1~10 (2020), 대한부인종양학회[DOI]
- US Preventive Services Task Force, "Screening for cervical cancer : US Preventive Services Task Force recommendation statement", JAMA, 320, pp.674~686 (2018)
- Walker EM, "A retrospective review of cervical cytology in women developing invasive squamous cell carcinoma", Br J Obstet Gynaecol, 90, pp.1087~1091 (1983)
- Janerich DT, "The screening histories of women with invasive cervical cancer, Connecticut", Am J Public Health, 85, pp.791~794 (1995)
- Wain GV, "The Papanicolaou smear histories of 237 patients with cervical cancer", Med J Aust, 157, pp.14~16 (1992)
- Fahey MT, "Meta-analysis of Pap test accuracy", Am J Epidemiol, 141, pp.680~689 (1995)
- Nanda K, "Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities : a systematic review", Ann Intern Med, 132, pp.810~819 (2000)
- Rylander E, "Negative smears in women developing invasive cervical cancer", Acta Obstet Gynecol Scand, 56, pp.115~118 (1977)
- 민경진, "The Korean guideline for cervical cancer screening", Journal of Gynecologic Oncology, 26(3), pp.232~239 (2015), 대한부인종양학회
- Solomon D, "The 2001 Bethesda system : terminology for reporting results of cervical cytology", JAMA, 287, pp.2114~2119 (2002)
- Maruvka YE, "On the validity of using increases in 5-year survival rates to measure success in the fight against cancer", PLoS One, 9, pp.e83100~ (2014)
- Rozemeijer K, "Cervical cancer incidence after normal cytological sample in routine screening using SurePath, ThinPrep, and conventional cytology: population based study", BMJ, 356, pp.j504~ (2017)
- Sawaya GF, "Risk of cervical cancer associated with extending the interval between cervical-cancer screenings", N Engl J Med, 349, pp.1501~1509 (2003)
- Stenkvist B, "Reasons for cervical cancer despite extensive screening", J Med Screen, 3, pp.204~207 (1996)
- Philp L, "Pap tests in the diagnosis of cervical cancer: help or hinder?", Gynecol Oncol, 150, pp.61~66 (2018)
- DeMay RM, "Cytopathology of false negatives preceding cervical carcinoma", Am J Obstet Gynecol, 175, pp.1110~1113 (1996)
- Zhao L, "Factors associated with reduced accuracy in Papanicolaou tests for patients with invasive cervical cancer", Cancer Cytopathol, 122, pp.694~701 (2014)
- Krane JF, "Papanicolaou smear sensitivity for the detection of adenocarcinoma of the cervix : a study of 49 cases", Cancer, 93, pp.8~15 (2001)
- Coldman A, "Risk of invasive cervical cancer after three consecutive negative Pap smears", J Med Screen, 10, pp.196~200 (2003)
- Etherington IJ, "Adenocarcinoma in situ of the cervix-controversies in diagnosis and treatment", J Low Genit Tract Dis, 5, pp.94~98 (2001)
- Katki HA, "Five-year risks of CIN 3+ and cervical cancer among women who test Pap-negative but are HPV-positive", J Low Genit Tract Dis, 17(5 Suppl 1), pp.S56~S63 (2013)
- Hildesheim A, "Risk factors for rapid-onset cervical cancer", Am J Obstet Gynecol, 180, pp.571~577 (1999)
- Prendiville W, "Carcinoma of cervix with recent normal Papanicolaou tests", Lancet, 2, pp.853~854 (1980)
- Morgan-Jones DV, "Misleading exfoliative cytology", Br Med J, 2, pp.874~875 (1964)